Gapping up
In reaction to earnings/guidance:
- LFST +22.4%, MAXN +15.9%, ARLO +11.8%, VERX +9.7%, ZYME +9.4%, MCG +8.5%, CRWD +5.8%, REVG +5%, LTH +4.3%, WTI +2.6%, KFY +2.5%, NVEI +2.4%, ABM +2.2%, CPB +2.1%, BASE +1.2%, CASY +0.9%, GSAT +0.8% (guidance)
Other news:
- KBAL +68.4% (HNI Corporation (HNI) to acquire Kimball International in a cash and stock transaction valued at approximately $485 mln)
- DSEY +38% (to be acquired by Solenis for $4.6 bln or $8.40/share)
- MESO +14.9% (receives FDA acceptance of resubmission of BLA for Remestemcel-L )
- WE +7.9% (to restructure $3 bln in debt according to NYT)
- DBVT +6.6% first patient screened in VITESSE Phase 3 trial)
- OXY +2.7% (Berkshire Hathaway (BRK.A / BRK.B) bought another 5801791 shares worth ~$354.5 mln (3/3-3/7 transaction dates))
- VRNA +1.9% (files mixed shelf)
- CDTX +1.8% (presents preclinical data)
- VLRS +1.1% (reports February traffic)
- BBIO +1.1% (prices offering of 8823530 shares of its common stock at a public offering price of $17.00 per share)
Analyst comments:
- AY +1.6% (upgraded to Buy from Neutral at BofA Securities)
- AGNC +1.3% (upgraded to Overweight from Neutral at JP Morgan)
- CMS +1.2% (upgraded to Buy from Neutral at BofA Securities)